High levels of inflammatory factors including chemokines have been reported in peritoneal fluid and blood of women with endometriosis. CXCL12 mediates its action by interaction with its specific receptor, CXCR4, reported to be elevated in human endometriosis lesions and in the rat model of endometriosis. Activation of the CXCR4-CXCL12 axis increases cell proliferation, migration, and invasion of cancer cells. To obtain insights into the CXCR4 expression profile in lesions and endometrium, as well as functionality of the CXCR4-CXCL12 axis in endometriosis, we analyzed the expression of CXCR4 in tissues on a human tissue array and studied CXCL12-mediated activation of proliferation, invasion, and migration in vitro. We observed differences in levels of nuclear CXCR4 expression among lesion types, being higher in ovarian lesions. Endometriotic cell lines (12Z) showed higher levels of CXCR4, proliferative and migratory potential, and AKT phosphorylation/kinase activity compared to untreated control cells (endometrial epithelial cells). CXCL12 and endometriotic stromal cell-enriched media increased proliferation of non-endometriotic epithelial cells. CXCL12 caused a significant increase in 12Z cell invasion but had no effect on migration; AMD3100, a CXCR4-specific inhibitor, significantly increased invasion of 12Z cells but decreased their migration. However, treatment with CXCL12 plus AMD3100 significantly decreased invasion and migration of 12Z cells. In conclusion, the CXCR4-CXCL12 axis is functional in endometriosis cells, but the expression of CXCR4 varies among lesions. CXCL12 -CXCL12 axis in endometriosis, 2018, Vol. 98, No. 1 5 promoted proliferation, migration, and invasion of endometriotic cells, while inducing AKT phosphorylation and activity, but pharmacologically blocking this axis in the absence of the ligand induced their invasiveness.
promoted proliferation, migration, and invasion of endometriotic cells, while inducing AKT phosphorylation and activity, but pharmacologically blocking this axis in the absence of the ligand induced their invasiveness.
Introduction
The pathologic mechanisms underlying endometriosis development and progression remain poorly understood, although genetic, epigenetic, environmental, and immune/inflammatory factors have been implicated. Most of the available treatments for endometriosis are hormones that cause undesired side effects while not being curative [1, 2] . Thus, a greater understanding of this complex and multifactorial disease and dissection of the biological and signal transduction mechanisms that contribute to its pathophysiology is needed in order to facilitate the identification of novel non-hormonal candidate therapeutic targets.
When CXCL12 binds its specific receptor, the G protein coupled receptor CXCR4, it activates mechanisms related to normal reproductive biology (e.g., menstruation, ovulation, trophoblast implantation, and parturition [3, 4] ) as well as immunity (e.g., natural killer cells and T cells [5] ). Hyperactivation of the CXCR4-CXCR12 axis results in disease processes such as tumorigenesis, invasion, and metastasis [6] . This axis is involved in various cancer cell behaviors that also characterize endometriosis (e.g., increased basal proliferation rates [7] [8] [9] ; and increased invasiveness [10] ). Although few, there are some studies providing support for the involvement of the CXCR4-CXCL12 axis in endometriosis: (i) there are high levels of inflammatory factors including chemokines in the peritoneal fluid and serum of women with endometriosis, including chemokines such as CXCL12 [11] [12] [13] [14] ; CXCL12 is overexpressed in endometriosis lesions compared to eutopic endometrium from patients and controls [15] [16] [17] ; (ii) CXCR4 protein expression is highest in both ovarian endometriosis and endometrial carcinoma when compared to normal ovary [18] ; (iii) global gene profiling of endometriotic lesions using laser-captured microdissected epithelial cells identified a 20-fold increased expression of CXCR4 when compared to normal endometrial epithelial cells (EEC) [19] ; and (iv) lesions from the rat model of endometriosis have higher levels of CXCR4 gene expression when compared to endometrium from controls [20] .
Based on these data, we hypothesized that the CXCR4-CXCL12 axis could play a role in the development or progression of endometriosis. Thus, the aim of this study was to obtain insights into the profile of expression across different lesions types and into the functionality of the CXCR4-CXCL12 axis in endometriosis, as a first step to explore the possibility of targeting this axis as a therapy for this incapacitating disease. We show here that there are functional interactions between CXCL12 and CXCR4 in endometriotic epithelial cells that leads to increased proliferation, invasion, and migration, as well as phosphorylation and activation of serine-threonine protein kinase (AKT), which may facilitate their ectopic survival and growth. However, we also show that there were unforeseen effects of the CXCR4 inhibitor that could preclude its clinical use in endometriosis as a single agent.
Materials and methods

Immunohistochemistry of CXCR4 in human endometriotic lesions on a tissue array
The endometriosis-focused tissue array used for this study has been previously described and used for other investigations [21] [22] [23] . All studies involving human tissues were approved by the Internal Review Board of the Ponce Health Sciences University (PHSU). A total of 164 deidentified endometriotic tissue blocks were used to construct a tissue array in collaboration with the PHSU-Moffitt Cancer Center Partnership. To account for the heterogeneity of endometriosis, this tissue array includes lesions localized in the ovaries (n = 29), fallopian tubes (n = 16), peritoneum (n = 34), skin (umbilical region) (n = 4), and gastrointestinal tract (n = 7). Additionally, the tissue array includes endometrial samples obtained from patients with endometriosis and controls (women undergoing hysterectomy for benign uterine disorders) in the proliferative and secretory phases of the menstrual cycle. All blocks were analyzed by two pathologists to document endometriosis (glands and stroma) and determine the menstrual cycle phase in the case of endometrium according to Noyes criteria [24] . The tissue array block was cut in 10 μm for immunostaining. Immunohistochemistry was conducted as described by Ruiz et al. [25] . Primary antibody against CXCR4 was used at a 1:300 dilution (R4 monoclonal-clone 44716) (R&D Systems Minneapolis, MN) (Table S1 ). Negative control for the immunostaining was done with normal serum instead of primary antibody in control tissue slides. Immunohistochemical staining (IHC) intensity was evaluated in glands and stroma using a semiquantitative method. Staining intensity was blindly scored as absent (0), weak (1), moderate (2), or intense (3) by two independent, blinded observers. Mean IHC intensity score and interquartile range were calculated per compartment per sample for statistical analysis.
Cell cultures
Human endometrial stromal cells (HESC), highly invasive and immortalized with human Telomerase reverse transcriptase (hTert), were purchased from American Type Culture Collection (#CRL 4003). Noninvasive epithelial cells (EEC, which have been shown to have MCF7 characteristics by DNA fingerprinting [26] ), and human endometriotic epithelial cells (12Z), SV40 T antigentransformed and derived from a peritoneal lesion, were obtained as part of a collaboration with Dr Fazleabas and Dr Starzinski [27] . The 12Z were grown Dulbecco's Modified Eagle's Medium (DMEM)/F12, 10% Fetal Bovine Serum (FBS); HESC were grown in phenol-free DMEM, charcoal-treated 10% FBS, 1% insulin-transferrin-selenium (ITS); the medium for EEC cells was DMEM/F12, 10% FBS, 160 ng/ml insulin as previously described [28, 29] . Endometriotic stromal cells derived from a peritoneal endometriotic lesion and grown at low passage numbers (Primary Endometriotic Cells (PED)) (developed in Dr Idhaliz Flores laboratory;
Bello et al. unpublished data) were cultured in complete DMEM supplemented with 10 −8 mol/L estradiol and 1% ITS. Estradiol and ITS were removed from media 24 h prior to experiments.
Enzyme-linked immunosorbent assay for CXCL12
The cell lines 12Z, PED, HESC, and EEC were cultured as previously described [21, 22] . The cells were cultured during 24, 48, and 72 h. Cell culture supernatant was collected, centrifuged, and stored in aliquots at -20
• C. Levels of human CXCL12 were determined using a Quantikine enzyme-linked immunosorbent assay (ELISA) (R&D systems, Minneapolis, MN) following manufacturer's instructions and as described before [30] . Briefly, the assay diluent was added to samples (in triplicate) and to the standards (serially diluted positive control), and incubated for 2 h at room temperature (RT). CXCL12-specific antibody was added to each well and incubated at RT for 2 h followed by washes. The substrate solution was then added to each well and incubated in the dark. Finally, the optical density was determined using a microplate reader (MRX Revelation, Dynex Technologies, Inc., Chantilly, VA) set to 450 nm with correction wavelength set at 540 nm.
Western blotting for CXCR4
Total protein extraction from the cell cultures, quantification, and western blot analysis have previously been described in detailed [31] . Dilutions of anti-CXCR4 (monoclonal-clone 44716) (R&D Systems Minneapolis, MN) and GAPDH (monoclonal-DM1A) (Calbiochem, Darmstadt, Germany) used were 1:300 and 1:1000, respectively (Table S1). Experiments were repeated three times.
Modulation of in vitro cell proliferation by CXCL12 or stromal cell-enriched media
The BrdU cell proliferation assay kit was used to study 12Z and EEC cell proliferation in response to CXCL12, primary endometriotic stromal cell (PED)-enriched media, or complete media as control, following the manufacturer's instructions (Millipore, Temecula, CA). The amount of the incorporated BrdU, indicative of newly synthesized DNA, was detected using a microplate reader (MRX Revelation, Dynex Technologies, Inc., Chantilly, VA) set at dual wavelengths of 450/550 nm. As blank we used cell media with no cells and as background cells without the BrdU reagent. To measure profilerative responses to CXCL12, epithelial cells (12Z or EEC) were seeded at 4000 and 2000 densities in 100 μl media in a flat bottom 96-well plate overnight. CXCL12 (hrCXCL12 alpha, R&D Systems, Inc., Minneapolis, MN) was added to the media to a final concentration of 10 and 100 ng/ml, and proliferation rates were measured by BrdU incorporation. These doses were based on a published study by Laird et al. [32] . To determine the proliferative effects of the stromal cell-enriched media on the epithelial cells (12Z and EEC), PED (primary endometriotic) and HESC (hTERT immortalized stromal endometrial) cells were cultured at a density of 1.0 × 10 6 cells in 2 ml per well in a 6-well plate without estrogen and ITS. After 24 h of culture, conditioned media was collected, filtered, and added to 12Z and EEC cells for 24 h. Proliferation rates were measured by BrdU incorporation following manufacturer's protocol. Experiments were repeated at least three times.
Modulation of phospho-AKT by CXCL12
Cells were grown and incubated with media containing 10 or 100 ng/ml of human recombinant (hr) CXCL12 alpha, or complete media as control, for 10 s, 1, 5, 10, 15, and 30 min. Cells were lysed with RIPA lysis buffer supplemented with protease and phosphatase inhibitors (Roche Diagnostics, Indianapolis, IN). Protein concentration was determined using a standard curve generated by a Bradford protein assay. Prior to Western Blot (WB), total AKT was immunoprecipitated. Briefly, proteins were diluted in lysis buffer containing protease and phosphatase inhibitors and 50 μl of Sepharose protein A (Rockland Gilbertsville, PA) was added, followed by addition of anti-AKT antibody or phospho-AKT (Cell Signaling Technology, Danvers, MA), and incubation overnight at 4
• C with gentle rocking. After centrifugation and washes, membranes were incubated with horseradish peroxidase-conjugated secondary antibody, and signals were detected with an automated image documentation system (ChemiDoc, Bio-Rad, Hercules). Band density was analyzed using Quantity One software (Bio-Rad, Hercules, CA). Experiments were repeated three times.
Modulation of AKT kinase activity by CXCL12
Cell lines (12Z and EEC) were cultured as previously described. Media containing 10 or 100 ng/ml CXCL12, or complete media as control, were added during 1, 10, 30 min. Cellular lysates were analyzed using a nonradioactive immunoprecipitation-kinase assay to detect total phospho-AKT at serine 473 and phosho-glycogen synthase kinase 3 (GSK-3)α/β(ser21/9) (AKT Kinase Activity kit, Cell Signaling Technology, Danvers, MA) following the manufacturer's protocol. In brief, after treatments, cells were lysed and sonicated 10 min on ice, followed by centrifugation. Cell lysates were incubated with beads/immobilized antibody overnight with gentle rocking at 4
• C. Cell lysate containing immobilized antibody was centrifuged, and after washes the pellet was suspended in 50 μl in kinase buffer supplemented with 1 μl of 10 nM ATP and the kinase substrate, GSK-3α/β fusion protein. Samples were incubated during 30 min at 30
• C. The reaction was terminated by adding 25 μl of 3× sodium dodecyl sulfate (SDS) buffer, vortex, and microcentrifugation. WB analyses were performed as previously described to detect phospho-AKT and phospho-GSK-3α/β. Experiments were performed in triplicate.
Modulation of in vitro migration and invasion by CXCL12 and/or AMD3100
Cell migration and invasion of 12Z and EEC in response to CXCL12 plus/minus the CXCR4-specific inhibitor AMD3100 (Sigma-Aldrich, St. Louis, MO) were quantified using BD BioCoat Matrigel Invasion Chamber following standard protocols (BD Biosciences, Bedford, MA). In brief, epithelial cells were grown in the upper chambers in complete media or media with 100 nM AMD3100. Complete media supplemented with 10 or 100 ng/ml CXCL12 was added to the lower chamber in 24-well plates. Wells with Matrigel-coated inserts or control inserts were used to differentiate invasion from migration, respectively [33, 34] . After 24 h, the cells were fixed and stained with Diff-Quik stain (Dade Behring, Inc. Newark, DE) following the manufacturer's instructions. The inserts were allowed to dry and mounted in microscope slides for counting and visualization of the invading and migrating cells using a light microscope. Experiments were repeated three times.
Statistical analyses
Data from cell culture experiments (e.g., proliferation, AKT phosphorylation, AKT function, migration and invasion) were analyzed by Mann-Whitney, non-parametric Student t-test, compared to basal or untreated conditions. Analysis of variance (ANOVA) using Tukey and Dunn multiple comparison tests was used to analyze tissue , and endometriotic epithelial (12Z) cells lines were cultured in complete media. Total protein was extracted, quantified, and separated by electrophoresis. Levels of CXCR4 were analyzed by immunoblotting, and GAPDH was used as loading control. At least three experiments in three different passage numbers were conducted. Differences in the levels of GAPDH can be explained by the different cell types (epithelial vs. stromal), which was normalized by densitometric analysis.
array immunostaining differences. All analyses were conducted using SPSS 15.0 (Chicago, IL, USA) and GraphPad Prizm v5 was used for graphical representation of the data. Statistical significance was set at P < 0.05.
Results
Immunostaining of CXCR4 in human endometrium and endometriotic lesions on a tissue array
We analyzed by IHC the protein expression of the chemokine receptor CXCR4 in human endometriosis lesions from five different anatomical sites (ovaries, peritoneum, fallopian tubes, skin, and gastrointestinal tract) as well as eutopic endometrium from women with endometriosis and controls included in a custom-made endometriosis-focused tissue array. From 164 samples, 137 core biopsies (84%) could be analyzed; biopsies that did not include stroma and glands were excluded from the analysis. Nuclear CXCR4 (nCXCR4) expression was in general higher in stroma compared to glands, and significantly higher in the stroma of ovarian endometriosis compared to fallopian tube lesions and proliferative endometrium from controls. In that respect, the proliferative endometrium from patients showed a similar expression of nCXCR4 than endometriotic lesions (Figure 1 ). nCXCR4 expression in glands was highest in ovarian compared to both fallopian lesions and proliferative endometrium from cases and controls. Cytoplasmic CXCR4 expression in stroma was not significantly different among the tissues analyzed, although lesions showed a slightly increased level of cCXCR4 expression compared to endometrial tissues (P = 0.0343).
In vitro CXCR4 and CXCL12 expression CXCR4 protein expression was analyzed in 12Z, HESC, and EEC by WB. We showed higher levels of CXCR4 expression in 12Z cells compared to EEC (Figure 2) . HESC, an endometrial stromal cells also expressed CXCR4. ELISA results showed that none of the cell lines studied (12Z, HESC, EEC, PED) expressed CXCL12 alpha, or its expression was below detection levels (data not shown). This contrasts with the findings of increased levels of CXCL12 in human endometriotic tissues. It is possible that other CXCL12 isoforms (from beta to gamma) not measured here are involved. Others have previously shown that endometrial stromal cell lines do not express CXCL12, contrary to what is seen in whole tissues [35] .
Effects of CXCL12 or stromal cell-conditioned media on in vitro proliferation rates
We next studied the proliferation rate of 12Z, HESC, and EEC using the BrdU proliferation assay. Our results confirmed that endometriotic epithelial cells, 12Z, had a statistically significant higher basal level proliferation rate compared to the control cell lines HESC and EEC ( Figure 3A) . Next, we studied the in vitro proliferative effects of CXCL12 in the studied cells lines using the BrdU proliferation assay. Treatment with CXCL12 for 24 h induced a significant increase in EEC cells proliferation rates by 33% (100 ng/ml) and 41% (200 ng/ml); despite expressing CXCR4 neither 12Z nor HESC cells responded to CXCL12 in this manner ( Figure 3B ). The epithelial cell lines 12Z and EEC were cultured in conditioned media from the stromal cell lines PED (endometriotic) and HESC (normal) to determine whether there are secreted factors that can induce proliferation of epithelial cells. As controls, neutralizing antibodies to CXCR4 or CXCL12 were added to the culture medium. 12Z cells cultured in media conditioned by HESC cells showed an increase in proliferation. However, this increase was not statistically significant nor was it reduced by the neutralizing antibodies to CXCR4 or CXCL12. EEC cells cultured with media conditioned by PED cells showed a statistically significant proliferation increase of 68% ( Figure 3C ). The proliferation increased observed in EEC cells cultured in conditioned media was not decreased by treatment with neutralizing antibodies to CXCR4 or CXCL12.
Effects of CXCL12 on AKT Serine 473 phosphorylation and AKT kinase activity
After normalization against total AKT and relative to basal expression, our data show that the levels of AKT phosphorylation were higher in the endometriotic 12Z cells compared to EEC cells at both CXCL12 doses tested (Figure 4) . The higher dose of CXCL12 (100 ng/ml) significantly increased AKT phosphorylation compared to the lower dose (10 ng/ml) (P < 0.05 at 1 min). Also, we observed significant increases in AKT kinase activity in 12Z cells induced by CXCL12 (10 ng/ml) at 1, 10, and 30 min of treatment compared to no treatment ( Figure 5 ). At the higher dose (100 ng/ml) and longer experimental time (30 min), CXCL12 treatment significantly decreased AKT activity in 12Z cells. In contrast, AKT activity was not significantly changed in EEC cells after treatment with 10 and 100 ng/ml CXCL12 at any of the times studied.
Effects of CXCL12 and/or the CXCR4 inhibitor AMD3100 in invasion and migration in vitro
We then determined the effects in invasion and migration of CXCL12 and/or the CXCR4 inhibitor AMD3100 in the epithelial cell lines (12Z or EEC) using the boyder chamber assay. CXCL12 alone (10 and 100 ng/ml) caused a significant increase in migration of 12Z cells; CXCL12 alone (10 ng/ml only) increased their invasion. AMD3100 alone significantly decreased migration of 12Z cells by 0.42-fold (P ≤ 0.0001) but increased their invasion capacity by 2.4-fold (P ≤ 0.0001) (Figure 6 ). Treatment with CXCL12 (10 ng/ml) plus AMD3100 significantly decreased invasion (P ≤ 0.01) and migration (P ≤ 0.0001) of 12Z cells. On the other hand, the migration capacity of EEC cells was significantly increased by CXCL12 alone (100 ng/ml) (P ≤ 0.01), but decreased by AMD3100 alone (P ≤ 0.001), and by CXCL12 plus AMD3100 (P ≤ 0.001). Invasiveness of EEC was decreased by AMD3100 alone or in combination with CXCL12, but this effect did not reach statistical significance.
Discussion
There are many reports of high levels of CXCR4 and its ligand, CXCL12, in endometriosis [18, 19, 31, [36] [37] [38] . Thus, it has been hypothesized that the CXCR4-CXCL12 axis might be an effective nonhormonal target for endometriosis, since blocking its action could interfere with activation of key disease mechanisms. To address this hypothesis, we assessed the protein expression profile of CXCR4 in glands and stroma of different types of endometriotic lesions, and studied cellular responses (proliferative, migratory, invasive) mediated by activation and blocking of the CXCR4-CXCL12 axis in vitro. Our study showed that pharmacologically blocking the CXCR4 receptor has contrasting effects depending on the presence of the ligand, and possibly on the concomitant expression of other receptors. These data support additional research on the mechanisms involved when this axis is targeted in the context of endometriosis, in order to support (or not) further evaluation of CXCR4-blocking drugs in preclinical studies and clinical trials. Immunohistochemical analysis of lesions on an endometriosisfocused tissue array showed that nuclear CXCR4 (nCXCR4) protein expression levels were generally higher in ectopic lesions compared to proliferative endometrium from controls, as shown by others [37, 38] . Our study of CXCR4 expression using a tissue array allowed us to document differences in the expression levels in different lesion types/localizations, and by cell type (glands vs. stroma). In general, expression of nCXCR4 protein was higher in the stromal compartment, and significantly higher in ovarian compared to fallopian tube lesions, which may be explained by different pathophysiological mechanisms underlying the various lesion types observed in patients. Notably, the expression of nCXCR4 in proliferative endometrium of controls was lower compared to secretory endometrium, while eutopic endometrium from patients had a level of nCXCR4 expression similar to that of ectopic lesions. Cytoplasmic expression of CXCR4, on the other hand, was higher in the glandular compartment, in accord with our own findings and those of others [39] , but we did not observe significant differences among tissue types. Nuclear localization of CXCR4 indicates activation of the receptor possibly leading to the endometriotic (A) (B) (C) (D) Figure 6 . Effects of CXCL12 and/or the CXCR4 inhibitor AMD3100 in invasion and migration. 12Z cells or EEC cells were cultured at the upper chamber at a 25 000 cell density; the bottom chamber media contained 10 or 100 ng/ml CXCL12, the CXCR4 inhibitor AMD3100 (100nM), or a combination of CXCL12 (100 ng/mL) and AMD3100 (100 nM). Cells were cultured for 24 h, followed by fixation, staining, and visualization of the cells under microscope to count the cells. (A and C) Number of cells counted in the control insert (migration). (B and D) Number of cells that invaded through the Matrigel matrix (invasion). Data were analyzed by comparing each treatment to media only using nonparametric Student t-test in GraphPad Prizm v5. Significance was set at P < 0.05 and represented by * P < 0.05, * * P < 0.01, * * * P < 0.005, * * * * P < 0.001.
phenotypes (i.e., proliferation, migration, invasion) that we observed here to be activated in vitro. It is important to highlight that activation of the CXCR4 receptor varied depending on lesion type/localization, being higher in ovarian lesions, which may impact response to therapy with CXCR4 blockers. For example, this treatment may be more effective in women with ovarian endometriosis in particular. CXCR4 is also expressed in eutopic endometrium from patients. This is important to document since the efficacy of pharmacological interventions for endometriosis via blocking this axis will likely depend on the levels of and the tissue expression profile of CXCR4. Also of interest is that CXCR4 is highly expressed in many cancers including ovarian, and that ovarian lesions have been associated with malignant transformation to ovarian cancers (endometrioid and clear cell types) [40, 41] . Whether CXCR4 could constitute a biomarker of transformation potential, alone or in combination with other markers (e.g., Ki67), needs to be studied further.
We also show here that the endometriotic epithelial cell line 12Z expresses higher basal levels of CXCR4 compared to the control cell lines, HESC and EEC. 12Z cells also had a higher proliferation when compared to the control cells, thus confirming previous observations [42] . CXCL12 did not increase the proliferation rate of 12Z cells despite them expressing the CXCR4 receptor. It is possible that 12Z cells already have a high basal proliferation rate that cannot be induced further by CXCR4-CXCL12 axis activation. In contrast, the epithelial cell line EEC did respond to CXCL12 by increasing its proliferation rate, showing that the ligand-receptor interaction used in these experiments is functional, and suggesting that this effect may be mediated by the CXCR4 receptor. The endometrial stromal cells HESC expressed CXCR4, as shown here, but no increase in proliferation was observed in response to treatment with CXCL12. It is possible that the receptor is nonfunctional because the interaction, function, or activities of G proteins are known to be cell contextdependent (i.e., epithelial vs stromal) [43] . In addition, other cellular responses could have been activated by the ligand through this receptor in the stromal cells, such as autophagy, that we did not assess in the present study [44] .
The proliferation of the epithelial control cells EEC, but not of 12Z cells, was induced by stromal cell-conditioned media (HESC and PED) cells compared to control media. The proliferative effect of the PED-conditioned media on EEC proliferation rates was not reduced by blocking CXCR4 or CXCL12 with neutralizing antibodies, suggesting that other secreted factors might be mediating this effect. In the context of endometriosis, it can be argued that the shed endometrium tissue reaching the peritoneal cavity could initiate an inflammatory reaction, and factors secreted by inflammatory cells (and also by the stromal component of the refluxed endometrium) could induce proliferation of the EEC. In addition, other relevant processes could be activated by numerous factors secreted into the peritoneal fluid, including degradation of extracellular matrix, adhesion, and angiogenesis leading to the development of ectopic lesions. It would be important that follow-up studies are conducted to identify the stromal-derived factor(s) that may be mediating the observed growth-promoting effects on epithelial cells.
It is well documented that the CXCR4-CXCL12 axis activates the AKT pathway; therefore, in order to assess its functionality in the cell lines studied, we conducted AKT phosphorylation and kinase activity assays. We observed that in the control epithelial cells (EEC), a transient increase in AKT phosphorylation was observed at the lowest dose of CXCL12. In contrast, there was an increase in AKT phosphorylation associated with the higher CXCL12, which was sustained for up to 30 min. Accordingly, we also observed sustained AKT kinase activity only in the endometriotic 12Z cells. Taken together, these results suggest that in endometriotic cells the AKT signaling pathway is more CXCL12-responsive (i.e., is differentially modulated by both incubation time and ligand concentration) than in the control cells, although in both cell lines this signaling pathway is functional (as demonstrated by GSK substrate phosphorylation). The observed higher levels of AKT activity induced by 10 ng/ml of CXCL12 in 12Z cells may explain in part the increased invasiveness induced by CXCL12, an effect that was not seen in the control cells at any of the dose studied. It is important to take into account that there are other pathways that can be activated by the CXCR4-CXCL12 axis, including phosphoinositol-3-kinase, mitogen-activated protein kinase, Src kinase, and focal adhesion (PyK2, FAK) pathways, which were not studied here [45] . Therefore, more studies are necessary to dissect the signal transduction mechanisms activated in response to CXCL12 in order to understand the contribution of chemokine to cellular functions relevant to endometriosis.
This study also demonstrated that the endometriotic epithelial cells 12Z have a higher basal migratory potential compared to the control epithelial cell line EEC. Treatment of 12Z cells with the CXCR4 antagonist, AMD3100, significantly decreased migration but, intriguingly, increased their invasion capacity. Combining the drug with CXCL12 counteracted this effect ( Figure 7) . Recently, an additional receptor, CXCR7, has been reported to bind to CXCL12 [46] . While limited, there is some evidence that CXCR7 is expressed by endometriotic lesions, endometrial cells, and endometrial cancer [47, 48] . AMD3100 is an allosteric agonist for CXCR7 [49] , known to bind and activate CXCR7, but the molecular effects resulting from this interaction are not well understood. We hypothesize that the CXCR4:CXCL12 interaction is primarily responsible for inducing migration of 12Z cells, while the CXCR7:CXCL12 interaction leads to invasion, a possibility that needs to be experimentally proven. AMD3100 by itself significantly decreased EEC migration, but none of the treatments (ligand, inhibitor, or their combination) induced their invasion. Taken together, these data suggest that the endometriotic epithelial cells migrate more in response to low concentrations of the ligand; these cells do not produce CXCL12 and can be more readily sensitive to exogenous sources of CXCL12 in the peritoneal environment. While their migration can be reduced by the CXCR4 inhibitor, treatment with this drug results in pleiotropic responses leading to increases in invasion, limiting its possible use as a candidate nonhormonal treatment for endometriosis unless it is given in combination with CXCL12.
In conclusion, our results provide evidence that CXCR4 is differentially expressed across lesion types, being highest in ovarian endometriosis. In addition, endometriotic epithelial cells (12Z) express high levels of CXCR4, are highly migratory, and have a functional CXCR4-CXCL12 axis. Finally, our data suggest that not all cancer-targeted drugs may also be effective in endometriosis despite both diseases sharing the same cellular behaviors. Therefore, before targeting this pathway therapeutically, additional experiments including preclinical investigations in animal models are needed to dissect the molecular pathways activated by CXCL12 alone or in combination with receptor blocking drugs.
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